Clinical effects of low-molecular-weight heparin combined with ulinastatin in children with acute pancreatitis by Han, Ai-Hua et al.
Han et al 
Trop J Pharm Res, August 2016; 15(8): 1787  
 
Tropical Journal of Pharmaceutical Research August 2016; 15 (8): 1787-1792 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v15i8.27 
Original Research Article 
 
 
Clinical effects of low-molecular-weight heparin combined 
with ulinastatin in children with acute pancreatitis 
 
Ai-Hua Han1*, Guo-Qing Yu1 and Hua-Zhen Yin2 
1Pediatric Surgery Department, 2Clinical Pharmaceutics Room, Binzhou People’s Hospital, Binzhou, 256600, PR China 
 
*For correspondence: Email: hahhantjpr@163.com 
 
Received: 17 February 2016        Revised accepted: 9 July 2016 
 
Abstract 
Purpose: To explore the clinical effects of low-molecular-weight heparin (LMWH) combined with 
ulinastatin (UTI) in children with acute pancreatitis. 
Methods: In total, 560 patients with severe acute pancreatitis treated at Binzhou People’s Hospital, 
Shandong, China, from April 2012 to June 2014 were enrolled in this study. They were divided into 
control (280 patients, ulinastatin + conventional treatment) and observational groups (280 patients, 
LMWH + ulinastatin + conventional treatment). The treatment lasted for 2 weeks. Clinical parameters, 
laboratory test indices, Acute Physiology and Chronic Health Evaluation (APACHE II) score, and 
computed tomography score of pancreatic necrosis (CTSPN) were assessed in both groups. 
Results: On admission, no significant differences were noted in clinical features, laboratory parameters, 
APACHE II scores, or CTSPN between the two groups (all p > 0.05). After 2 weeks of treatment, serum 
amylase, urine amylase, prothrombin time, fibrinogen, partial thromboplastin time, and platelet count in 
the study group were 913 ± 281 U/L, 1893 ± 295 U/L,  16 ± 1.60 s, 3 ± 0.60 g/L, 39.80 ± 5.60 s, and 294 
± 49 × 109/L, respectively, all of which were similar or superior to those in the control group (1738 ± 346 
U/L, 2453 ± 473 U/L, 15 ± 1.50 S, 2.50 ± 0.50, 39.80 ± 5.90, and 192 ± 37 × 109/L)). APACHE II scores 
and CTSPN after 2 weeks of treatment in the observation group were 8.50 ± 1.80 and 2.10 ± 1, 
respectively, which were superior to those in the control group (9.60 ± 2.40 and 4.30 ± 2.60, 
respectively; p < 0.05). Moreover, the incidence of complications, mortality rate, and average duration of 
the hospital stay in the observation group were lower than those in the control group (p > 0.05). The 
cure rate in the observation group was higher than that in the control group. 
Conclusions: LMWH combined with UTI enhances the efficacy of conventional treatment and reduces 
mortality. Thus, it is a potentially effective treatment strategy for severe acute pancreatitis in children.  
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Severe acute pancreatitis is a special category of 
acute pancreatitis with multiple complications 
and a high mortality rate, accounting for 10 to 20 
% of all cases of acute pancreatitis [1]. Severe 
paediatric acute pancreatitis, which is rarely 
seen, can be induced by multiple factors and 
usually presents with symptoms of acute or 
intermittent abdominal pain. It is easily ignored or 
misdiagnosed at an early stage, and non-surgical 
therapy remains the major treatment [2,3]. It has 
been found that effectively inhibiting the 
activation and release of pancreatin, cell factors, 
and inflammatory factors; improving the 
microcirculation; and adjusting the internal 
environment in the early period are of great 
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significance in the prognosis of severe acute 
pancreatitis [4]. 
 
In recent years, many researchers have explored 
treatment methods for severe acute pancreatitis. 
In traditional Chinese medicine, researchers 
have usually chosen to use Rheum officinale, 
Salvia miltiorrhiza, and peach seed to treat 
severe acute pancreatitis. In Western medicine, 
various new drugs have emerged, such as 
enzyme inhibitors (e.g., octreotide and 
somatostatin), anti-pancreatin drugs, and 
cytokine inhibitors (e.g., lexipafant). 
 
However, the curative effects of these drugs are 
unsatisfactory. Thus, the search for new 
therapies remains a focus of pancreatitis 
research. Ulinastatin (UTI) is a broad-spectrum 
trypsin inhibitor and can slow disease 
progression by effectively restraining the 
secretion of pancreatic tissue enzyme and 
reducing the dissolution and damage to 
pancreatic tissue by pancreatin [5]. Low-
molecular-weight heparin (LMWH) can improve 
the microcirculation by inhibiting the activity of 
thrombin and blood coagulation factors as well 
as platelet aggregation and reducing the risk of a 
temporary platelet clot transforming into a more 
permanent fibrous clot. Moreover, it can reduce 
the expression of proinflammatory factors and 
nuclear factor-κB (NF-κB) induced by endotoxins. 
Its anti-inflammatory effects may include down-
regulating the expression of inflammatory 
mediators by lowering the expression of 
adhesion molecules [6]. 
 
Few studies have addressed the application of 
UTI and LMWH in treating severe paediatric 
acute pancreatitis. Thus, to further assess the 
clinical effects of LMWH in combination with UTI 
in treating severe paediatric acute pancreatitis, 
560 children with severe acute pancreatitis were 






In total, 560 children with severe acute 
pancreatitis who were treated in Binzhou 
People’s Hospital from April 2012 to June 2014 
were selected for this study. All children satisfied 
the diagnostic and classificatory criteria for acute 
pancreatitis [7], and children who developed 
other chronic diseases, dysfunction in vital 
organs, and had drug contraindications were 
excluded. The patients comprised 332 boys and 
228 girls aged 2 to 10 years (average, 5.31 ± 
2.23 years). They were divided randomly into a 
control group (UTI group) and an observation 
group (LMWH + UTI group), with 280 children in 
each group.  
 
Family members of all patients provided written 
informed consent. This study was approved by 
the medical ethics committee of Binzhou 
People’s Hospital (approval no. 
HAH20150623BZ) and conformed to the 
principles of the Declaration of Helsinki [8].   
 
Evaluation of APACHE II and CTSPN indices  
 
The Acute Physiology and Chronic Health 
Evaluation (APACHE II) scoring system consists 
of an acute physiological score, which includes 
12 physiological parameters, an age score, and 
chronic health conditions. A higher score 
indicates a more severe disease condition. The 
computed tomography score of pancreatic 
necrosis (CTSPN) consists of the computed 
tomography severity index (CTSI), which equals 
the grade of acute pancreatitis + the degree of 
pancreatic necrosis. Severity was divided into 
three levels: level I (0 – 3 points), level II (4 – 6 
points), and level III (7 – 10 points). Levels II and 
III are considered severe. Changes in laboratory 
indexes, including serum amylase (AMS), urine 
AMS, prothrombin time (PT), fibrinogen (FIB), 
partial thromboplastin time (PTT), platelet count 
(PLT), the clinical curative status, and the 
occurrence of complications were also observed. 
 
Evaluation criteria for curative effect  
 
The patients were considered cured if their 
severe acute pancreatitis-related symptoms and 
abnormal vital signs resolved and associated 
examination results returned to normal levels. 
The treatment was deemed effective if the 
severe acute pancreatitis-related symptoms and 
vital signs showed differing degrees of 
improvement and associated examination results 
basically recovered to normal levels. However, 
the treatment was deemed ineffective if the 
severe acute pancreatitis-related symptoms, 
abnormal vital signs, and associated examination 
results showed no obvious changes; the disease 
continued to progress; or the patient died. The 
following formula was used to calculate the cure 
rate: (number of cured cases + number of 




SPSS software (ver. 19.0, IBM Corp, Armonk, 
NY, USA) was used to analyse the data. Data 
are expressed as mean ± standard deviation. 
Comparisons between groups were performed 
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using the t-test, and comparisons of parameters 
before and after treatment were performed used 
the paired t-test. Differences were considered 




Comparison between groups 
 
There were 280 patients in the observation group 
(178 boys, 102 girls; age, 3 – 9 years; average, 
5.14 ± 2.13 years) and 280 patients in the control 
group (154 boys, 126 girls; age, 2 – 10 years; 
average, 5.25 ± 2.32 years). Differences in 
general data, such as sex and age, between the 
groups were not statistically significant (p > 
0.05). Thus, the groups were comparable. 
 
Changes after treatment 
 
The APACHE II scores and CTSPN at admission 
were not significantly different between the 
groups (p > 0.05). After 2 weeks of treatment, the 
APACHE II scores and CTSPN in the 
observation group were significantly lower than 
those in the control group (p < 0.05) (Table 1). 
 
Changes in biochemical parameters  
 
There was no significant difference (p > 0.05) in 
the blood or urine AMS between the two groups 
on admission. After 2 weeks of treatment, AMS 
in the observation group was clearly lower than 
that in the control group (p < 0.01). Differences in 
PT, FIB, PTT, and PLT between the two groups 
showed no statistical significance (p > 0.05) 
when patients were admitted to the hospital. 
After 2 weeks of treatment, FIB in the control 
group decreased markedly. There was no 





Several complications occurred in the control 
group during treatment: 92 (32.90 %) cases of 
acute respiratory distress syndrome (ARDS); 26 
(9.20 %) cases of mild upper gastrointestinal 
haemorrhage, of which 12 (4.20 %) involved 
abdominal and subcutaneous haemorrhage; and 
56 (21.50 %) cases of failure of two or more 
organs.  
Table 1: Changes in APACHE II scores and CTSPN 
 
Group 
APACHE II score CTSPN 
Initial After 2-week treatment Initial 
After 2-week 
treatment 
A 11.60±3.60 8.50±1.80* 5.40±1.90 2.10±1* 
B 11.50±3.40 9.60±2.40* 5±1.50 4.30±2.60 
t value 0.239 4.339 0.934 4.396 
p value >0.05 <0.05 >0.05 <0.05 
Observation group: A; Control group: B. Data are presented as mean ± standard deviation; *p < 0.05 vs. before 
treatment 
  
Table 2: Changes in biochemical parameters before and after treatment 
 
Group 
Blood AMS (U/L) Urine AMS (U/L) PT (s) 





A 3629±963 913±281** 5677±981 1893±295** 15±1.80 16±1.60 
B 3684±895 1738±346* 5723±993 2453±473* 15±1.50 15±1.50 
t-value 0.571 11.977 0.429 11.886 0.491 5.395 




FBI (g/L) PTT (s) PLT (×109/L) 





A 3.60±0.90 3±0.60 36.50±40 39.80±5.60 180±19 294±49 
B 3.50±0.70 2.50±0.50 35.70±3.90 39.80±5.90 180±17 192±37 
t-value 0.571 11.977 0.429 11.886 0.491 5.395 
P-value >0.05 <0.05 >0.05 <0.05 >0.05 <0.05 
Observation group: A; Control group: B. Data are presented as mean ± standard deviation; *p < 0.05 vs. before 
treatment 
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Complications in the observation group included 
34 (12.10 %) cases of ARDS, 10 (3.60 %) cases 
of upper gastrointestinal haemorrhage, and 24 
(8.50 %) cases of failure of two or more organs. 
Thus, the incidence of organ failure and ARDS 
was significantly higher in the control than 
observation group (p < 0.05). 
 
Comparison of clinical efficacy 
 
The recovery rate in the control group (64.30 %, 
180/280) was clearly lower than that in the 
observation group (86.40 %, 242/280; p < 0.05). 
In the control group, 30 patients underwent 
surgery (including necrotic pancreatic tissue 
removal) and 16 patients underwent abdominal 
washing and drainage. In the observation group, 
12 patients underwent surgery and 2 underwent 
abdominal washing and drainage. The difference 
in surgery rates between the groups was 
statistically significant (p > 0.05). The mortality 
rate in the control group (28.60 %, 80/280) was 
much higher than that in the observation group 
(10%, 28/280). Deaths in both groups were the 
result of multiple organ failure. The average 
hospital stay in the control group was 43 ± 11 
days, and that in the observation group was 30 ± 




Although research on the pathogenesis and 
mechanisms of severe acute pancreatitis has 
progressed in recent years, the primary cause of 
the high mortality remains unknown. Severe 
acute pancreatitis develops gradually, 
progressing from autodigestion and free radical 
injury to excessive activation of white blood cells, 
secondary strike, and microcirculatory 
disturbances [9,10]. 
 
Currently, several researchers consider 
inflammatory mediators and microcirculatory 
disturbances to play important roles in the 
occurrence and development of severe acute 
pancreatitis, which provides a theoretical basis 
for the use of anti-coagulation drugs. UTI, a 
Kunitz-type broad-spectrum protease inhibitor, 
has two incompletely overlapping functional 
areas and can inhibit the activity of multiple 
proteases and hydrolytic enzymes [11]. UTI can 
stabilise the activity of enzymes in the cell 
membrane, regulate ion disorders inside and 
outside cells, prevent overload of calcium ion 
inside cells, improve blood perfusion in local 
tissues, and recover electrical activity and normal 
form and function in damaged tissues and 
organs [12]. Moreover, UTI can prevent liver and 
renal function damage, reduce systemic 
inflammatory reactions, and increase the 
success rate of surgery in patients with severe 
acute pancreatitis in the perioperative period 
[13]. 
 
As an anticoagulation drug, LMWH can 
effectively restrain the activity of thrombin and 
blood coagulation factor Xa, inhibit platelet 
aggregation, and improve the microcirculation. 
LMWH can also reduce inflammation by lowering 
the expression of pro-inflammatory factors, 
inflammatory factors, adhesive factors, and NF-
κB induced by endotoxins [14]. Experimental and 
clinical studies [15,16] have found that LMWH 
can lower the expression of tumour necrosis 
factor-α and interleukin-6; reduce the risk of 
microthrombus formation; relieve microcirculatory 
issues in the pancreas, kidney, lung, and brain; 
and lower the fatality rate in patients with severe 
acute pancreatitis by down-regulating the 
expression of serum endothelin-I and the activity 
of NF-κB. Mishreki et al [17] compared the 
curative effects and safety of LMWH and 
unfractionated heparin in the treatment of deep 
venous thrombosis and found that LMWH had a 
better curative effect and better safety. 
 
In this study, the curative effects of the 
combination of the two drugs and UTI alone in 
the treatment of severe acute pancreatitis were 
compared. The results showed obvious 
improvements in laboratory indices, much higher 
cure rate, and lower incidence of complications in 
the observation than in the control group, 
suggesting that LMWH plus UTI is safe and 
effective for treatment of severe acute 
pancreatitis. In the early stages of severe acute 
pancreatitis, LMWH could reduce white blood 
cell-induced peroxidation damage and cell 
factors by improving the microcirculation and 
decreasing the adhesion and transfer of white 
blood cells into tissues. In later stages, the anti-
inflammatory effects of UTI affected the 
connection between inflammatory factors and 
white blood cells, stopped disease progression, 
improved the microcirculation, and prevented 
shock, ischaemia-reperfusion injury, and multiple 
organ dysfunction syndrome. 
 
Furthermore, the results showed that the decline 
in APACHE-II scores in the observation group 
was larger than that in the control group. 
APACHE-II score is an optimal index for 
evaluating the development of acute pancreatitis 
and the touchstone of clinical comparative 
studies [18]. Karimgani et al [19] observed 
APACHE-II scores in 26 patients with acute 
pancreatitis on admission and at 48 h and found 
a significant difference between the survival and 
death groups (6.90 ± 0.80 vs. 13 ± 2.50 and 8.90 
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± 1.10 vs. 16.50 ± 3, respectively; p < 0.05). 
Because vital organs are involved in severe 
pancreatitis, APACHE-II scores show an obvious 
increase in the early stage (0 – 48 h) and the 
increase becomes faster at 24 to 48 h. A 
continued increase in APACHE-II scores after 
discharge usually indicates disease progression. 
In this study, the APACHE-II scores in the 
observation group were much lower than those in 
the control group after treatment, suggesting that 
the combination of LMWH plus UTI can relieve 
severe acute pancreatitis-related inflammation 
and reduce the incidence of complications. 
 
Balthazar et al [20] proposed CTSI criteria in 
1990. The CTSI may reflect peripancreatic 
effusion as well as the degree of pancreatic 
necrosis. Moreover, it can be used to reflect the 
incidence of complications and the death rate in 
patients with acute pancreatitis. Leung et al [21] 
considered that a CTSI of ≥5 points indicates an 
increase in the incidence of complications, an 
extension of the average length of hospital stay, 
and an increase in the death rate of patients with 
severe acute pancreatitis. The CTSI is a useful 
tool for evaluating the severity and prognosis of 
severe acute pancreatitis, and it is more sensitive 
than the APACHE-II score. This study found that 
the CTSI scores of patients in the two groups 
showed no significant difference on admission, 
but after 2 weeks of treatment, the CTSI in both 
groups declined; the decrease in the observation 
group was more obvious than that in the control 
group. This suggests that UTI in combination 
with LMWH was effective in relieving pancreatic 
and peripancreatic lesions. 
 
Limitations of the study 
 
This study found that UTI in combination with 
LMWH had a marked effect in the treatment of 
acute pancreatitis. However, the difference in 
surgery rate between the groups was not 
statistically significant, due possibly to the small 
sample size. Thus, larger studies are needed to 




This study found that UTI, which inhibits 
pancreatic enzyme secretion, and LMWH, which 
improves microcirculation, are two important 
drugs in non-surgical treatment of acute 
pancreatitis. The two drugs act at different 
stages, significantly improving the curative effect. 
UTI in combination with LMWH can rapidly 
relieve abdominal pain, reduce complications, 
shorten the length of hospital stay, and enhance 
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